Matches in Wikidata for { <http://www.wikidata.org/entity/Q38439813> ?p ?o ?g. }
- Q38439813 description "2015 nî lūn-bûn" @default.
- Q38439813 description "2015年の論文" @default.
- Q38439813 description "2015年論文" @default.
- Q38439813 description "2015年論文" @default.
- Q38439813 description "2015年論文" @default.
- Q38439813 description "2015年論文" @default.
- Q38439813 description "2015年論文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015年论文" @default.
- Q38439813 description "2015년 논문" @default.
- Q38439813 description "article científic" @default.
- Q38439813 description "article scientific" @default.
- Q38439813 description "article scientifique" @default.
- Q38439813 description "articol științific" @default.
- Q38439813 description "articolo scientifico" @default.
- Q38439813 description "artigo científico" @default.
- Q38439813 description "artigo científico" @default.
- Q38439813 description "artigo científico" @default.
- Q38439813 description "artikel ilmiah" @default.
- Q38439813 description "artikull shkencor" @default.
- Q38439813 description "artikulong pang-agham" @default.
- Q38439813 description "artykuł naukowy" @default.
- Q38439813 description "artículo científico" @default.
- Q38439813 description "artículu científicu espublizáu en 2015" @default.
- Q38439813 description "bilimsel makale" @default.
- Q38439813 description "bài báo khoa học" @default.
- Q38439813 description "naučni članak" @default.
- Q38439813 description "scienca artikolo" @default.
- Q38439813 description "scientific article published on 24 April 2015" @default.
- Q38439813 description "scientific article published on 24 April 2015" @default.
- Q38439813 description "scientific article published on 24 April 2015" @default.
- Q38439813 description "teaduslik artikkel" @default.
- Q38439813 description "tieteellinen artikkeli" @default.
- Q38439813 description "tudományos cikk" @default.
- Q38439813 description "vedecký článok" @default.
- Q38439813 description "vetenskaplig artikel" @default.
- Q38439813 description "videnskabelig artikel" @default.
- Q38439813 description "vitenskapelig artikkel" @default.
- Q38439813 description "vitskapeleg artikkel" @default.
- Q38439813 description "vědecký článek" @default.
- Q38439813 description "wetenschappelijk artikel" @default.
- Q38439813 description "wissenschaftlicher Artikel" @default.
- Q38439813 description "επιστημονικό άρθρο" @default.
- Q38439813 description "мақолаи илмӣ" @default.
- Q38439813 description "наукова стаття, опублікована у квітні 2015" @default.
- Q38439813 description "научна статия" @default.
- Q38439813 description "научная статья" @default.
- Q38439813 description "научни чланак" @default.
- Q38439813 description "научни чланак" @default.
- Q38439813 description "מאמר מדעי" @default.
- Q38439813 description "مقالة علمية نشرت في 24 أبريل 2015" @default.
- Q38439813 description "বৈজ্ঞানিক নিবন্ধ" @default.
- Q38439813 description "บทความทางวิทยาศาสตร์" @default.
- Q38439813 description "სამეცნიერო სტატია" @default.
- Q38439813 name "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 name "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 name "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 type Item @default.
- Q38439813 label "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 label "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 label "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 prefLabel "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 prefLabel "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 prefLabel "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 P1433 Q38439813-754851AD-6038-4CC0-9B9C-FFB64F3A6C60 @default.
- Q38439813 P1476 Q38439813-E7AC0969-7DC8-4A91-A8F8-8DA83A362DBB @default.
- Q38439813 P2093 Q38439813-00B8ACAC-CBFC-4151-8E1C-A3440216548C @default.
- Q38439813 P2093 Q38439813-12EF358D-FF1D-4E25-A6BA-B1926C4F11C4 @default.
- Q38439813 P2093 Q38439813-22EAAE45-E886-434F-A019-65E2116EC6CB @default.
- Q38439813 P2093 Q38439813-32CE70AE-2E62-4349-A1CB-EFFB5B8C7673 @default.
- Q38439813 P2093 Q38439813-7FD4AF2D-DD01-41E6-AF01-FF58A099B3E6 @default.
- Q38439813 P2093 Q38439813-8785C553-55CD-4DBB-88F1-169CE1318AF4 @default.
- Q38439813 P2093 Q38439813-92ED448B-E7F6-4726-9792-8C4D26132744 @default.
- Q38439813 P2093 Q38439813-BF34A77F-2E7C-4628-B92A-3FC900196E65 @default.
- Q38439813 P2093 Q38439813-C3C5660A-AD97-4259-A165-F4E79D3BA714 @default.
- Q38439813 P2093 Q38439813-D350A946-5FF3-4CE1-AB5C-ADE86E9DC974 @default.
- Q38439813 P2093 Q38439813-ED465875-AED0-4A36-AA51-F3949739C8D8 @default.
- Q38439813 P2093 Q38439813-EF445B6F-EEDB-49A5-9463-9798FB1E065A @default.
- Q38439813 P304 Q38439813-73B32BA9-C552-4FB7-8C2E-1EB154D3F373 @default.
- Q38439813 P31 Q38439813-109885D2-3BD2-41BB-AE28-CF432C8096D3 @default.
- Q38439813 P31 Q38439813-1506ed20-5c7a-4d64-9fa6-f20ce05234be @default.
- Q38439813 P31 Q38439813-887c0d88-e5da-46da-a1a4-19b3310f21d9 @default.
- Q38439813 P356 Q38439813-4A3443AD-4384-4468-A9F5-7B1BD0AE9DDD @default.
- Q38439813 P407 Q38439813-CD794E9A-6EED-47CF-9341-C65780C83154 @default.
- Q38439813 P433 Q38439813-04A71D50-BBCC-46DF-B525-5E825A83F1B8 @default.
- Q38439813 P478 Q38439813-5077DFCF-4720-4175-8A7A-E80659CE1FCF @default.
- Q38439813 P50 Q38439813-9F433B58-D65B-420D-9E8D-E2EF0FF206BB @default.
- Q38439813 P577 Q38439813-FB3CB260-6BCC-4246-BAA9-0CB1BE68E19A @default.
- Q38439813 P698 Q38439813-9AC2E7A1-A256-4696-98C2-C0CB9878CD75 @default.
- Q38439813 P921 Q38439813-4D354024-6041-40A1-BE68-1FCEF9903BF3 @default.
- Q38439813 P921 Q38439813-8DAAC6B3-AF4A-4EBD-B3BF-A98EE408AFAF @default.
- Q38439813 P356 BJH.13463 @default.
- Q38439813 P698 25907897 @default.
- Q38439813 P1433 Q4970200 @default.
- Q38439813 P1476 "Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis" @default.
- Q38439813 P2093 "Allison Rago" @default.